JP2005187480A5 - - Google Patents

Download PDF

Info

Publication number
JP2005187480A5
JP2005187480A5 JP2005049791A JP2005049791A JP2005187480A5 JP 2005187480 A5 JP2005187480 A5 JP 2005187480A5 JP 2005049791 A JP2005049791 A JP 2005049791A JP 2005049791 A JP2005049791 A JP 2005049791A JP 2005187480 A5 JP2005187480 A5 JP 2005187480A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005049791A
Other languages
Japanese (ja)
Other versions
JP2005187480A (ja
Filing date
Publication date
Priority claimed from US08/030,644 external-priority patent/US5348942A/en
Application filed filed Critical
Publication of JP2005187480A publication Critical patent/JP2005187480A/ja
Publication of JP2005187480A5 publication Critical patent/JP2005187480A5/ja
Pending legal-status Critical Current

Links

JP2005049791A 1993-03-12 2005-02-24 殺菌／透過性増加タンパク質産物の治療用途 Pending JP2005187480A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/030,644 US5348942A (en) 1993-03-12 1993-03-12 Therapeutic uses of bactericidal/permeability increasing protein products
US9320293A 1993-07-15 1993-07-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP6520214A Division JPH08509703A (ja) 1993-03-12 1994-03-11 殺菌／透過性増加タンパク質産物の治療用途

Publications (2)

Publication Number Publication Date
JP2005187480A JP2005187480A (ja) 2005-07-14
JP2005187480A5 true JP2005187480A5 (enExample) 2006-02-23

Family

ID=26706282

Family Applications (3)

Application Number Title Priority Date Filing Date
JP6520214A Ceased JPH08509703A (ja) 1993-03-12 1994-03-11 殺菌／透過性増加タンパク質産物の治療用途
JP2005049792A Pending JP2005206606A (ja) 1993-03-12 2005-02-24 殺菌／透過性増加タンパク質産物の治療用途
JP2005049791A Pending JP2005187480A (ja) 1993-03-12 2005-02-24 殺菌／透過性増加タンパク質産物の治療用途

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP6520214A Ceased JPH08509703A (ja) 1993-03-12 1994-03-11 殺菌／透過性増加タンパク質産物の治療用途
JP2005049792A Pending JP2005206606A (ja) 1993-03-12 2005-02-24 殺菌／透過性増加タンパク質産物の治療用途

Country Status (15)

Country Link
US (3) US5639727A (enExample)
EP (2) EP1129718A3 (enExample)
JP (3) JPH08509703A (enExample)
CN (2) CN1105574C (enExample)
AT (1) ATE202482T1 (enExample)
AU (1) AU684503B2 (enExample)
CA (1) CA2157927C (enExample)
DE (1) DE69427582T2 (enExample)
DK (1) DK0690720T3 (enExample)
ES (1) ES2157981T3 (enExample)
GR (1) GR3036686T3 (enExample)
MX (1) MX9401807A (enExample)
NZ (1) NZ263057A (enExample)
PT (1) PT690720E (enExample)
WO (1) WO1994020128A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US6214789B1 (en) 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
AU684503B2 (en) * 1993-03-12 1997-12-18 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5731415A (en) * 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
AU7330994A (en) * 1993-07-14 1995-02-13 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
ES2178656T3 (es) * 1993-09-22 2003-01-01 Xoma Technology Ltd Metodo para tratar infeccion bacteriana gram-negativa por administracion de productos de proteina bactericida que aumenta la permebilidad(bpi) y antibioticos.
CA2181164C (en) * 1994-01-14 2008-01-08 Arnold Horwitz Anti-gram-positive bacterial methods and materials
DE69526216T2 (de) * 1994-01-14 2002-11-14 Xoma Technology Ltd., Berkeley Antifungaleverfahren und mitteln
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
JPH10508576A (ja) * 1994-09-15 1998-08-25 ゾーマ コーポレイション 抗真菌性ペプチド
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
CA2227292A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
DK0914144T3 (da) * 1996-05-10 2001-04-09 Univ Texas Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
NZ332954A (en) * 1996-05-23 2000-07-28 Xoma Corp Use of BPI protein products to treat humans with hemorrhage due to trauma
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
AU3352799A (en) * 1997-10-31 1999-08-23 Children's Medical Center Corporation Method for regulating size and growth of vascularized normal tissue
US6264596B1 (en) 1997-11-03 2001-07-24 Meadox Medicals, Inc. In-situ radioactive medical device
US7238662B2 (en) * 1997-12-18 2007-07-03 Ambryx Biotechnology, Inc. Alpha 2HS glycoprotein for treatment of cancer and a method for preparation thereof
US5994298A (en) * 1997-12-18 1999-11-30 Tsai; David Proteins for cancer cell specific induction of apoptosis and method for isolation thereof
US6737402B2 (en) 1997-12-18 2004-05-18 David Tsai Method of preparing fetuin to induce apoptosis
US6720311B2 (en) 1997-12-18 2004-04-13 David Tsai Polypeptide for the treatment of cancer and a method for preparation thereof
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6242219B1 (en) * 1999-03-18 2001-06-05 Xoma (Us) Llc Methods for recombinant peptide production
US6515104B1 (en) * 1999-06-25 2003-02-04 Xoma Technology Ltd. Therapeutic peptide-based constructs derived from domain II of bactericidal/permeability-increasing protein
US6964948B2 (en) * 1999-06-25 2005-11-15 Xoma Technology Ltd. Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein
JP2004517865A (ja) * 2000-12-01 2004-06-17 ゾーマ テクノロジー リミテッド Ｂｐｉタンパク質産物またはｂｐｉインヒビターを使用する、周皮細胞増殖の調節
EP1492874B1 (en) 2002-03-29 2011-01-19 XOMA Technology Ltd. Multigenic vector plasmids and methods for increasing expression of recombinant polypeptides
EP1741440A1 (en) 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
BR112012026542A2 (pt) 2010-04-16 2016-07-12 Momenta Pharmaceuticals Inc abordagem seletiva de tecido
WO2011159770A2 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
WO2012138839A1 (en) * 2011-04-05 2012-10-11 Dana-Farber Cancer Institute, Inc. Bpi and its congeners as radiation mitigators and radiation protectors
JP2016520613A (ja) 2013-05-28 2016-07-14 モメンタ ファーマシューティカルズ インコーポレイテッド 薬学的組成物
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
IT201700108102A1 (it) * 2017-09-27 2019-03-27 Univ Degli Studi Padova Composizione di bactericidal/permeability increasing protein e acido ialuronico per il trattamento delle artropatie
WO2019063320A1 (en) 2017-09-27 2019-04-04 Universita' Degli Studi Di Padova COMPOSITION COMPRISING A BACTERICIDE / PERMEABILITY INCREASING PROTEIN AND HYALURONIC ACID FOR THE TREATMENT OF ARTHROPATHIES
EP3566717A1 (en) 2018-05-09 2019-11-13 Universität Regensburg Bactericidal/permeability increasing protein for use in a method of immunization, preferably as an adjuvant in a method of vaccination

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
DE3856588T2 (de) * 1987-08-11 2006-09-07 New York University Biologisch-aktive Bakterizide/permeabilitätserhöhende Proteinbruchstücke
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5221664A (en) * 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
JPH06504262A (ja) * 1990-07-27 1994-05-19 レブリゲン　コーポレーション 脈管形成性の病気の処置用の新規な方法と組成物
AU9127591A (en) * 1990-12-03 1992-06-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5357041A (en) * 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin
EP0576669A4 (en) * 1992-01-16 1996-05-08 Repligen Corp Novel methods and compositions for treatment of angiogenic diseases
US5491130A (en) * 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
AU684503B2 (en) * 1993-03-12 1997-12-18 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products

Similar Documents

Publication Publication Date Title
BE2021C524I2 (enExample)
BE2021C519I2 (enExample)
BE2020C508I2 (enExample)
BE2020C004I2 (enExample)
BE2019C503I2 (enExample)
BE2019C533I2 (enExample)
BE2013C014I2 (enExample)
BE2012C042I2 (enExample)
BRPI0601402B8 (pt) Aplicador de grampos cirúrgicos
BR122017004707A2 (enExample)
JP2005187480A5 (enExample)
JP2005206606A5 (enExample)
IN2007KO03049A (enExample)
JP2006175594A5 (enExample)
BRPI0609157A8 (enExample)
BRPI0608519A2 (enExample)
JP2006275764A5 (enExample)
CU23910B1 (enExample)
BR122016029989A2 (enExample)
JP2006195385A5 (enExample)
JP2005337253A5 (enExample)
BRPI0604219A (enExample)
JP2006021930A5 (enExample)
JP2006202842A5 (enExample)
BRPI0618215B8 (enExample)